LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Accueil・Liste d'Actions・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Fermé

SecteurSoins de santé

21.22 -3.15

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

21.03

Max

21.48

Chiffres clés
By Trading Economics
Revenu	-29M -11M
Ventes	-24M 105M
BPA	-0.09
Marge bénéficiaire	-10.717
Employés	354
EBITDA	-31M -8.5M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+58.82% upside

Dividendes
By Dow Jones
Prochains Résultats	5 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-252M 2.7B
Ouverture précédente	24.37
Clôture précédente	21.22

Sentiment de l'Actualité

By Acuity

29%

71%

82 / 344 Classement par Healthcare

Arcutis Biotherapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

5 juin 2026, 19:20 UTC

Principaux Mouvements du Marché

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5 juin 2026, 21:27 UTC

Résultats

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 juin 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5 juin 2026, 20:20 UTC

Acquisitions, Fusions, Rachats

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 juin 2026, 20:19 UTC

Acquisitions, Fusions, Rachats

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 juin 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 juin 2026, 19:26 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 juin 2026, 19:26 UTC

Market Talk

Hog Futures Tumble to Close Week -- Market Talk

5 juin 2026, 19:10 UTC

Market Talk

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 juin 2026, 19:03 UTC

Market Talk

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 juin 2026, 18:59 UTC

Market Talk

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 juin 2026, 18:47 UTC

Market Talk

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 juin 2026, 18:34 UTC

Market Talk

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 juin 2026, 18:33 UTC

Acquisitions, Fusions, Rachats

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 juin 2026, 17:50 UTC

Résultats

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 juin 2026, 17:27 UTC

Market Talk

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 juin 2026, 16:48 UTC

Acquisitions, Fusions, Rachats

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 juin 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 juin 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

5 juin 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

5 juin 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 juin 2026, 15:44 UTC

Acquisitions, Fusions, Rachats

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 juin 2026, 15:26 UTC

Market Talk

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5 juin 2026, 15:25 UTC

Résultats

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5 juin 2026, 15:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 juin 2026, 15:16 UTC

Market Talk

Zcash Tumbles After Exploit Found -- Market Talk

5 juin 2026, 15:09 UTC

Market Talk

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5 juin 2026, 15:07 UTC

Market Talk

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5 juin 2026, 15:05 UTC

Market Talk

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Comparaison

Variation de prix

Arcutis Biotherapeutics Inc prévision

Objectif de Prix

By TipRanks

58.82% hausse

Prévisions sur 12 Mois

Moyen 34.86 USD 58.82%

Haut 36 USD

Bas 34 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

7 ratings

Achat

Maintien

Vente

Basé sur 7 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

82 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.